In the Phase 2 retatrutide trial ( Jastreboff et al., NEJM 2023 ), body-composition imaging showed fat mass falling substantially more than lean mass, meaning the majority of the weight lost was fat
This means that food stays inside them for longer, contributing to the sense of fullness and this in turn contributes to people's desire to eat less
For semaglutide, the relevant secondary patents include: Formulation patents covering the specific inactive ingredients, pH buffers, and stabilizers that keep semaglutide stable in solution (US 9,714,283, expires 2033) Method-of-use patents covering specific dosing schedules and titration protocols (US 10,195,214, expires 2032) Delivery device patents for the pen injector mechanism used in Ozempic and Wegovy (separate patent family, expires 2029-2031) Oral formulation patents for the SNAC (salcaprozate sodium) absorption enhancer used in Rybelsus tablets (US 9,931,349, expires 2032) The expiration date that matters to you depends on which formulation you care about
For commercial insurance, outcomes depend entirely on your specific plan
Brown label (1 mg) The brown-labeled pen delivers 1 mg of semaglutide in 0.5 mL